Did You Acquire (XCUR) Before January 7, 2021? Should Management Be Held Accountable for Investors Losses? Contact Johnson Fistel

San Diego, California--(Newsfile Corp. - February 17, 2022) - Johnson Fistel, LLP is investigating potential claims on behalf of Exicure, Inc. ("Exicure" or the "Company") (NASDAQ: XCUR) against certain of its officers and directors.

Recently, a class action complaint was filed against Exicure. According to the complaint, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that there had been certain improprieties in Exicure's preclinical program for the treatment of Friedreich's ataxia; (2) that Exicure lacked effective internal controls over the collection, analysis, and dissemination of data relating to Exicure's preclinical program for the treatment of Friedreich's ataxia; (3) that, as a result, the Company misreported the efficacy of XCUR-FXN in various public presentations and SEC filings from (at least) January 7, 2021 through August 12, 2021; (4) that, as a result, the Company would have to suspend its development of XCUR-FXN for the treatment of Friedreich's ataxia; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you are a current, long-term shareholder of Exicure holding shares before January 7, 2022, you may have standing to hold Exicure harmless from the alleged harm caused by the Company's officers and directors by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.

To join this action, you can go to: https://www.cognitoforms.com/JohnsonFistel/ExicureInc2 or [Click here to join this action]. There is no cost or obligation to you.

If you are interested in learning more about the investigation, please contact lead analyst Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If emailing, please include a phone number.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. Johnson Fistel seeks to recover losses incurred due to violations of federal securities laws. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com

To join this action, you can go to: https://www.cognitoforms.com/JohnsonFistel/ExicureInc2 or [Click here to join this action]. There is no cost or obligation to you.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/114116

info